[go: up one dir, main page]

WO2009036906A1 - Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation - Google Patents

Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation Download PDF

Info

Publication number
WO2009036906A1
WO2009036906A1 PCT/EP2008/007346 EP2008007346W WO2009036906A1 WO 2009036906 A1 WO2009036906 A1 WO 2009036906A1 EP 2008007346 W EP2008007346 W EP 2008007346W WO 2009036906 A1 WO2009036906 A1 WO 2009036906A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
group
constipation
laxatives
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/007346
Other languages
German (de)
English (en)
Inventor
Marianne Petersen-Braun
Ulrike Weingärtner
Brigitte Havertz
Thomas Schnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40044033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009036906(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Priority to DE112008002398T priority Critical patent/DE112008002398A5/de
Publication of WO2009036906A1 publication Critical patent/WO2009036906A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a composition with a combination of active ingredients for the treatment of constipation.
  • the invention further relates to the use of the active compound combinations according to the invention for the therapeutic treatment of constipation.
  • Constipation i. Stool constipation, occurs when the stool frequency is lowered; especially if there are less than three bowel movements per week.
  • the chair is usually hard and lumpy. Furthermore, defecation is usually possible only under strong pressing and associated with pain. This can lead to the affected patients avoiding bowel movements, which further worsens the condition.
  • constipation can be manifold. Often there is a functional disorder of the intestinal motility, which is due to a low-fiber diet, insufficient fluid intake and lack of physical exercise. For example, transient constipation may be triggered by disruption of the defecation rhythm due to external circumstances (e.g., travel).
  • constipation can be a symptom of various diseases, such as diabetic constipation or irritable bowel syndrome, Parkinson's disease or multiple sclerosis.
  • constipation is a common side effect of various medications, such as iron supplements, certain analgesics (especially opioids), blood pressure and heart medications, and sleeping pills and antidepressants.
  • various medications such as iron supplements, certain analgesics (especially opioids), blood pressure and heart medications, and sleeping pills and antidepressants.
  • the known laxative substances can be distinguished according to their mode of action as follows:
  • osmotic laxatives include saline
  • Laxatives such as Epsom salt (magnesium sulfate) and Glauber's salt (sodium sulfate decahydrate); poorly absorbable sugars and sugar alcohols, such as lactose, lactulose, lactitol, sorbitol, mannitol, xylitol; and polyethylene glycol (Macrogol), which binds the water with which it is taken to and transported into the colon, where it softens the stool and increases the intestinal volume, so that by stretching the
  • the macrogols are admixed with an electrolyte mixture (sodium, potassium, magnesium and / or calcium salts) in physiological concentration for the preparation of an iso-osmolar drinking solution.
  • an electrolyte mixture sodium, potassium, magnesium and / or calcium salts
  • Motility and secretion-inducing laxatives which stimulate the intestinal motility and cause the faster transport of the intestinal contents less water can be withdrawn.
  • These include the herbal laxatives containing anthranoid, such as aloe, buckthorn, rhubarb and the sennosides, and also the castor oil that irritates the intestinal wall.
  • the bisacodyl and sodium picosulfate series of diphenol synthetic laxatives inhibit the absorption of water and increase the secretion of water and electrolytes, resulting in stool softening, volume augmentation and peristalsis stimulation.
  • Lubricants e.g. Glycerin, paraffinum subliquidum and sodium dioctylsulfosuccinate, thereby making the feces more lubricious.
  • the object underlying the present invention was therefore to provide compositions for the treatment of constipation, in which the aforementioned disadvantages do not occur or at least to a lesser extent.
  • the object was to provide compositions of the type mentioned, which are suitable for eliminating constipation, and which additionally bring about a reduction or elimination of the flatulence associated with constipation.
  • this object is achieved according to the present invention by providing a composition which contains at least one selected from the group of laxatives active ingredient and at least one active ingredient from the group of defoamers in combination.
  • this combination is a fixed combination.
  • Such a combination of active ingredients not only enables a successful treatment of constipation, but at the same time a reduction or elimination of the bloating associated with constipation. Due to the presence of said defoamer in the combination of active ingredients, a possibly existing bulking effect of the laxative agent administered together with the combination of active substances is reliably suppressed.
  • compositions of the invention are characterized by an overall improved compatibility.
  • composition of the invention is obtained in one embodiment of the invention by simultaneously taking at least one selected from the group of laxatives active ingredient and at least one active substance from the group of defoamers.
  • compositions according to the invention contain a combination of active ingredients in the form of a "fixed combination"; This means that all active substances which form the respective active ingredient combination are present together in a dosage form and are administered together.
  • active substances from the group of defoamers are all substances or formulations which have pronounced interfacial activity and are suitable for suppressing undesired foaming or destroying an already formed foam, and which are furthermore pharmacologically harmless
  • dimethicone, simethicone or mixtures of dimethicone and simethicone are preferably used as defoamers, or preparations containing said antifoams.
  • simethicone refers to mixtures of dimethicone with Sihcagel (Sihciumdioxid, especially fumed Sihciumdioxid) Dimethicone and simethicone are included as effective ingredients in many Karminativa / Antiflatulenzia These defoamer substances are considered physiologically harmless, as they act mainly physically and the body in unchanged Leaving mold again The defoamer substances dimethicone and simethicone can be incorporated into liquid or solid administration forms with the addition of known excipients
  • the proportion of defoamer, in particular of dimethicone or simethicone, in a composition according to the invention is preferably 0.1 to 500 mg, particularly preferably 10 to 250 mg, and in particular 40 to 150 mg, in each case based on a single dose of the respective composition,
  • Suitable active ingredients from the group of laxatives are, in particular, salinic or osmotically active laxatives, antiresorptive and / or secretagogue-acting laxatives, intestinal peristalsis-demanding laxatives, as well as fillers and bulking agents and lubricants. These may be both synthetic substances and mixtures of substances Natural substances and mixtures, in particular of plant origin, act laxatives, which can be used for the purposes of the present invention and which are suitable for therapeutic use in humans or animals, are known to the skilled person. Likewise, the therapeutically suitable dosages of the individual active substances are Specialist known
  • Suitable creamy or osmotically active laxatives are, in particular, substances from the following group Macrogols (polyethylene glycols), in particular Macrogol 4000 and Macrogol 3350 with and without added electrolytes, lactulose, lactose, sugar alcohols, in particular sorbitol, Mannitol and xylitol; Sodium sulfate decahydrate (Glauber's salt), magnesium sulfate (Epsom salt), magnesium hydroxide, sodium lauryl sulfoacetate, disodium hydrogen phosphate,
  • anthraglycosides eg sennosides or buckthorn bovine glycosides
  • anthraquinones eg from aloe or rhubarb
  • Emodine aglycones of anthraglycosides
  • Ricinoleic acid castor oil
  • diphenolic laxatives e.g., bile acids
  • bile acids e.g., deoxycholic acid
  • cholagogues cholekinetic agents, e.g., ingredients of Curcuma species.
  • diphenolic laxatives in particular sodium picosulfate and bisacodyl are preferred; furthermore, phenolphthalein is also considered.
  • the diphenolic laxatives cause a dose-dependent increase of the electrolyte and water secretion into the colonic lumen, as well as an excitation of intestinal peristalsis.
  • a single dose of a composition according to the invention preferably contains 1 to 20 mg, more preferably 5 to 10 mg, bisacodyl or sodium picosulfate. In the case of phenolphthalein, a single dose preferably contains from 20 to 100 mg of this active ingredient.
  • said composition contains one or more plant-removing agents.
  • plant-removing agents may in particular be senna leaves, senna fruits, pineapple fruits, buckthorn bark, rhubarb root or Chelidonium majus, as well as extracts produced from these plants or parts of plants.
  • plant-removing agents may in particular be senna leaves, senna fruits, pineapple fruits, buckthorn bark, rhubarb root or Chelidonium majus, as well as extracts produced from these plants or parts of plants.
  • the composition contains one or more laxative substances from the group of fillers and bulking agents, in particular from the group of dietary fibers.
  • laxative substances from the group of fillers and bulking agents, in particular from the group of dietary fibers.
  • linseed, agar-agar, methylcellulose, psyllium (Plantago afra), wheat bran, soy bran, guar gum are mentioned in this context.
  • composition according to the invention contains at least one laxative substance from the group of lubricants. From this group in particular the following substances are considered: Glycerin, thick paraffin.
  • laxatives may each be contained as a single active substance in the fixed combination, or else as a combination of two or more laxatives. It is also provided that laxatives of different drug classes are combined, for example, an antiresorptive Laxans in combination with an osmotically effective laxative, or herbal laxatives (eg senna leaves or sennosides) in combination with chemically defined laxatives such as bisacodyl or Natriumpicosulfat.
  • an antiresorptive Laxans in combination with an osmotically effective laxative
  • herbal laxatives eg senna leaves or sennosides
  • chemically defined laxatives such as bisacodyl or Natriumpicosulfat.
  • composition according to the invention contains one of the following, preferably fixed, active ingredient combinations mentioned below:
  • g) in combination with at least one sugar alcohol preferably a sugar alcohol selected from the group consisting of sorbitol, mannitol and xylitol, or
  • saline laxatives preferably selected from the sodium sulfate decahydrate (Glauber's salt), magnesium sulfate (Epsom salt), magnesium hydroxide, sodium lauryl sulfoacetate, disodium hydrogen phosphate and
  • saline laxatives preferably selected from the group consisting of the sodium sulfate decahydrate (Glauber's salt), magnesium sulfate (Epsom salt), magnesium hydroxide, sodium lauryl sulfoacetate, disodium hydrogen phosphate and sodium dihydrogen phosphate.
  • the substances exemplified in the preceding paragraphs do not represent a complete and exhaustive list of active substances or groups of active ingredients. Of course, other active substances from the named groups of active substances and from other groups of active substances not mentioned here can also be used within the meaning of the invention.
  • the active substances according to the invention can also be used in the form of their pharmaceutically acceptable salts.
  • suitable salts are: hydrochloride, hydrobromide, sodium salts, phosphate, nitrate, sulfate, acetate, fumarate, citrate, propionate, oxalate, succinate, lactate, butyrate, methanesulfonate, aspartate, decanoate, maleate, tartrate, hydrogen tartrate.
  • compositions of the invention may be understood as pharmaceutical compositions, drugs or medical devices and may be formulated as solid, semi-solid or liquid dosage forms, preferably as a suspension (eg drops, juices), emulsion, clysma, gel, capsule, powder, granules, tablet, chewable tablet , Dragee, enteric-coated tablet, enteric-coated capsule, clyster, suppository or enema.
  • these are administration forms for oral or rectal administration.
  • the active ingredients mentioned above can be present in the compositions, in particular in particulate, dispersed, dissolved, suspended or emulsified form.
  • the total active ingredient content of the compositions of the invention is preferably in the range of 0.05 to 90 wt .-%, preferably in the range of 0.1 to 50 wt .-%, particularly preferably 0.5 to 20 wt .-%, each based on the total weight of the drug.
  • the proportion of active ingredient is determined in a manner known to the person skilled in the art, depending on the respectively selected dosage form, of the selected active ingredient (s) and the dose suitable for the respective therapeutic purpose.
  • the therapeutically suitable dosages of the individual active ingredients are known to the person skilled in the art.
  • Suitable adjuvants which are suitable for the preparation of the medicaments according to the invention are, for example, the following: particulate carriers (eg starch, starch derivatives, diatomaceous earth); gel-forming substances (eg gelatin, tragacanth, cellulose derivatives, alginates, polyacrylic acid); Emulsifiers (eg sorbitan esters, monoglycerides, glycerol stearate); Antioxidants (eg, ascorbic acid), thickening agents (eg, hydroxypropylmethylcellulose), pH corrigents, and buffering agents; Binders (eg polyvinylpyrrolidone, starch, Hydroxypropylmethylcellulose, polyethylene glycols), fillers (eg microcrystalline cellulose, sorbitol), dyes, flavors and flavorings (eg mint, vanilla, fruit flavors), sweeteners (eg sorbitol, aspartame); Solvents (eg water, ethanol, ethanol-water mixtures); Solubiliz
  • the present invention further relates to the use of said active substance combinations which contain at least one active substance selected from the group of laxatives and at least one active substance from the group of defoamers for the treatment of constipation. Furthermore, the invention extends to the use of compositions which, as described above, contain a combination of active substances according to the invention for the treatment of constipation.
  • the active compound combinations according to the invention can be used for the treatment of constipation of different etiology, duration, intensity or severity.
  • the therapeutic use according to the invention comprises both the treatment of chronic and acutely occurring constipations.
  • the invention further extends to the therapeutic treatment of constipation that occurs as a side effect of drugs, especially in opiate pain therapy, and for the treatment of diabetic constipation, constipation after surgery, constipation in bed restlessness, constipation in irritable bowel syndrome, constipation when changing diet, or to travel.
  • the active compound combinations or medicaments according to the invention are used to reduce or eliminate the occurrence of a painful and sudden fecal challenge.
  • the active compound combinations according to the invention are administered in suitable dosage forms, as described above, preferably by oral or rectal route.
  • suitable dosage forms are particularly suitable: suspension, emulsion, gel, capsule, powder, granules, tablet, chewable tablet, effervescent tablet, effervescent powder or dragee.
  • compositions according to the invention are used in the field of human medicine, ie for the treatment of persons suffering from constipation.
  • the invention also extends to the use of the active ingredient combinations and medicaments according to the invention in the field of veterinary medicine, ie for the treatment of animals, in particular farm animals or domestic animals, in which a treatment-related constipation has occurred.
  • the invention further includes methods for the therapeutic treatment of a person suffering from constipation who requires therapeutic treatment.
  • a therapeutic method has at least one treatment step in which a combination of active substances according to the invention in a therapeutically effective dose (or a composition according to the invention which contains such an active ingredient combination) is preferably administered by oral or rectal route. If necessary, the administration is repeated at appropriate intervals until the desired treatment success occurs.
  • a combination of active substances according to the invention in a therapeutically effective dose or a composition according to the invention which contains such an active ingredient combination
  • the administration is repeated at appropriate intervals until the desired treatment success occurs.
  • one to three single doses e.g., chewable tablet or suppository
  • the invention also extends to the use of a preferably fixed combination of active substances, as described above, for the production of medicaments or medical products for the treatment of constipation.
  • Constipation compared to conventional compositions to reduce the dose of the individual substances.
  • a reduction in side effects e.g., flatulence and sudden and painful stool urgency
  • side effects of laxative therapy e.g. reduced bloating, regardless of the mode of action of the laxatives, i. systemic or local.
  • Active Ingredients bisacodyl 5 mg (per tablet, total: 1.2 g), simethicone 50 mg (per tablet)
  • Excipients glycerol monostearate, hydroxypropylcellulose, sucrose, glucose, peppermint oil.
  • Example 2 enteric coated dragées for the treatment of constipation
  • Excipients polyvidone, lactose, croscarmellose sodium, macrogol 8000, enteric coating (Eudragit® S 100).
  • Example 3 suppositories for the treatment of constipation
  • Excipients medium-chain triglycerides, hard fat, corn starch.
  • Active Ingredients Macrogol 3350 13.121 g, simethicone 0.125 g, sodium chloride 0.350 g, sodium bicarbonate 0.179 g, potassium chloride 0.046 g
  • Excipients flavorings, sweeteners, glucose, sucrose, microcrystalline cellulose, hyetellose, etc.
  • Example 6 Lefax liquid capsule for simultaneous administration with a conventional laxative
  • Excipients soft capsule: gelatin, glycerol 85%, dry matter from polysorbitol and quinoline yellow (E104) ..
  • Observational parameters were: stool frequency and stool condition (hard, normal, slightly soft, diarrhea), time to defecation after taking the laxative, concomitant symptoms such as bloating, distended abdomen, pain and diarrhea.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition comprenant, en combinaison, au moins un principe actif choisi dans le groupe des laxatifs et au moins un principe actif choisi dans le groupe des agents antimoussants, pour le traitement thérapeutique de la constipation. L'invention concerne en outre l'utilisation d'une telle combinaison de principes actifs pour le traitement de la constipation.
PCT/EP2008/007346 2007-09-22 2008-09-09 Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation Ceased WO2009036906A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112008002398T DE112008002398A5 (de) 2007-09-22 2008-09-09 Zusammensetzung mit Wirkstoffkombination aus einem Laxans und einem Entschäumer zur Behandlung von Obstipation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07018665 2007-09-22
EP07018665.5 2007-09-22

Publications (1)

Publication Number Publication Date
WO2009036906A1 true WO2009036906A1 (fr) 2009-03-26

Family

ID=40044033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/007346 Ceased WO2009036906A1 (fr) 2007-09-22 2008-09-09 Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation

Country Status (7)

Country Link
AR (1) AR068530A1 (fr)
CL (1) CL2008002758A1 (fr)
DE (1) DE112008002398A5 (fr)
PE (1) PE20091192A1 (fr)
TW (1) TW200930385A (fr)
UY (1) UY31343A1 (fr)
WO (1) WO2009036906A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737537A1 (fr) * 2004-04-13 2007-01-03 Boehringer Ingelheim International GmbH Utilisation de la simethicone pour traiter des patients constipes
DE102012024434A1 (de) 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
EP2898893A1 (fr) * 2014-01-23 2015-07-29 Miklos Varhalmi Compositions améliorées de cholagogue pour traiter les gênes du tractus digestif et biliaire
US9468686B2 (en) 2009-07-30 2016-10-18 Norgine Bv Solutions comprising polyethylene glycol and electrolytes
CN107787223A (zh) * 2015-06-22 2018-03-09 西梯茜生命工学股份有限公司 肠道清洁用泻剂组合物
US11602509B2 (en) 2018-05-22 2023-03-14 Recordati Industria Chimica E Farmaceutica Spa Salt of cysteamine for the preparation of highly respirable particles
US11759493B2 (en) 2017-09-27 2023-09-19 Neilos S.r.l. Composition for the treatment of constipation
AU2024287244B1 (en) * 2024-12-28 2025-08-21 Lai, Meng Hong MR A device for relieving constipation and its preparation method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020071872A1 (en) * 1999-09-07 2002-06-13 Mcnally Gerard P. Laxative composition
WO2005055934A2 (fr) * 2003-12-05 2005-06-23 Ganeden Biotech, Incorporated Procedes de gestion alimentaire du syndrome du colon irritable et de la malabsorption des glucides
WO2005099821A1 (fr) * 2004-04-13 2005-10-27 Boehringer Ingelheim International Gmbh Utilisation de la simethicone pour traiter des patients constipes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020071872A1 (en) * 1999-09-07 2002-06-13 Mcnally Gerard P. Laxative composition
WO2005055934A2 (fr) * 2003-12-05 2005-06-23 Ganeden Biotech, Incorporated Procedes de gestion alimentaire du syndrome du colon irritable et de la malabsorption des glucides
WO2005099821A1 (fr) * 2004-04-13 2005-10-27 Boehringer Ingelheim International Gmbh Utilisation de la simethicone pour traiter des patients constipes

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737537A1 (fr) * 2004-04-13 2007-01-03 Boehringer Ingelheim International GmbH Utilisation de la simethicone pour traiter des patients constipes
US9468686B2 (en) 2009-07-30 2016-10-18 Norgine Bv Solutions comprising polyethylene glycol and electrolytes
DE102012024434A1 (de) 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
WO2014090223A3 (fr) * 2012-12-14 2014-10-09 Regalismons S.A. Compositions et solutions pour le lavage intestinal
US10617761B2 (en) 2012-12-14 2020-04-14 Regalismons S.A. Compositions and solutions for colon cleansing
EP2898893A1 (fr) * 2014-01-23 2015-07-29 Miklos Varhalmi Compositions améliorées de cholagogue pour traiter les gênes du tractus digestif et biliaire
CN107787223A (zh) * 2015-06-22 2018-03-09 西梯茜生命工学股份有限公司 肠道清洁用泻剂组合物
US20180318234A1 (en) * 2015-06-22 2018-11-08 Ctc Bio, Inc. Purgative composition for cleansing intestinal tract
EP3311814A4 (fr) * 2015-06-22 2019-02-27 CTC Bio, Inc. Composition purgative pour le lavage du tractus intestinal
US11759493B2 (en) 2017-09-27 2023-09-19 Neilos S.r.l. Composition for the treatment of constipation
US11602509B2 (en) 2018-05-22 2023-03-14 Recordati Industria Chimica E Farmaceutica Spa Salt of cysteamine for the preparation of highly respirable particles
AU2024287244B1 (en) * 2024-12-28 2025-08-21 Lai, Meng Hong MR A device for relieving constipation and its preparation method

Also Published As

Publication number Publication date
AR068530A1 (es) 2009-11-18
DE112008002398A5 (de) 2010-07-29
UY31343A1 (es) 2009-03-31
TW200930385A (en) 2009-07-16
PE20091192A1 (es) 2009-08-02
CL2008002758A1 (es) 2009-08-14

Similar Documents

Publication Publication Date Title
DE69720985T2 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE69822822T2 (de) Verwendung einer Zusammensetzung enthaltend Capsaicin oder Resiniferatoxin zur Behandlung des Reizdarmsyndroms
DE3856018T2 (de) Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung
DE60026459T2 (de) Simethicon enthaltendes Abführmittel
WO2009036906A1 (fr) Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation
EP0125634B1 (fr) Utilisation d'une substance sécrétolytique pour l'obtention d'un agent contre le ronflement et pour combattre le phénomène de ronflement
EP2099462A1 (fr) Préparation pharmaceutique pour le traitement de pathologies inflammatoires du système urogénital
WO2001022955A2 (fr) Nouvelle association de loteprednol et de produits antihistaminiques
DE68913907T2 (de) Methode zur Behandlung des interstitiellen Blasenentzündung.
DE69905384T2 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
EP2029101A2 (fr) Comprimé plat combiné pour le diabète de type 2
CH662734A5 (de) Antischnarchmittel.
DE3139005A1 (de) Pharmazeutische zubereitung mit anti-ischaemischer wirkung
DE602004008737T2 (de) Chondroitinsulfat enthaltende Zusammensetzung
EP2688577B1 (fr) Composition reductrice des symptomes de troubles digestifs
DE69902999T2 (de) Glucocorticoide zur behandlung von glomerulonephitis
EP1001756B1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
EP1834640A2 (fr) Agonistes d'yopiats kappa pour le traitement de maladies vésicales
DE102006027791A1 (de) AchE-NMDA-Kombinationswafer
DE102012024434A1 (de) Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
EP0002803B1 (fr) Cis triméthyl-3,3,5 cyclohexanol utilisable dans le traitement des maladies bilieuses
EP1210945B1 (fr) Composition pharmaceutique anti-artériosclérotique
DE3317558A1 (de) Orales antischnarchmittel
EP3687313B1 (fr) Composition pour le traitement de la constipation
EP3687314B1 (fr) Composition pour le traitement de la constipation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785846

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1120080023980

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 93062008

Country of ref document: AT

Kind code of ref document: A

REF Corresponds to

Ref document number: 112008002398

Country of ref document: DE

Date of ref document: 20100729

Kind code of ref document: P

122 Ep: pct application non-entry in european phase

Ref document number: 08785846

Country of ref document: EP

Kind code of ref document: A1